Lilly’s Type 2 Diabetes Candidate Succeeds in Phase 3 Trial

Eli Lilly’s Trulicity showed positive results in a Phase 3 trial, demonstrating more effectiveness in combination with a sulfonylurea in lowering hemoglobin A1c from baseline after 24 weeks of treatment than a sulfonylurea alone.

According to Lilly, 55.3 percent patients receiving Trulicity (dulaglutide) — a once-weekly glucagon-like peptide-1 receptor for the treatment of Type 2 diabetes — plus a sulfonylurea achieved an A1C of less than 7 percent, while only 18.9 percent of patients treated with a sulfonylurea and placebo saw the same result.

The most commonly reported adverse effects of the drug were gastrointestinal, such as nausea and diarrhea. More patients in the Trulicity group also experienced episodes of hypoglycemia.